Long‐term survival of two patients with recurrent high‐risk neuroblastoma

2021 ◽  
Author(s):  
Tomonobu Sato ◽  
Kazuya Hara ◽  
Go Ohba ◽  
Hiroshi Yamamoto ◽  
Akihiro Iguchi
Keyword(s):  
High Risk ◽  
Term Survival ◽  
Long Term Survival

Abstract 2143: Improved Long-Term Survival in a High Risk Population Following Drug Eluting Stent Availability

Circulation ◽  
2007 ◽  
Vol 116 (suppl_16) ◽  
Author(s):  
Maheer Gandhavadi ◽  
Kendrick A Shunk ◽  
Edward J McNulty
Keyword(s):  
High Risk ◽  
Independent Predictor ◽  
Drug Eluting Stent ◽  
High Risk Population ◽  
Term Survival ◽  
Risk Population ◽  
Long Term Survival ◽  
Drug Eluting ◽  
The Impact

Background Data regarding the impact of drug eluting stent (DES) use on long-term outcomes outside trial populations are limited. Methods 1,547 consecutive patients underwent stent implantation from January 2000 until December 2006 at the San Francisco Veterans Affairs Medical Center. To assess the impact of DES availability on mortality, that population was partitioned into a pre-DES cohort (N=591) and a post-DES availability cohort (N=956). Kaplan-Meier survival curves for the two cohorts were compared. Results The entire population was relatively high risk: 37% had diabetes, 38% a reduced ejection fraction, and 53% a prior MI or elevated troponin prior to the procedure. Median follow up was 4.7 years for the pre-DES cohort and 1.8 years for the post-DES cohort. DES were used in 83% of procedures in the post-DES cohort. Survival improved significantly in the post-DES cohort (P = .04, Log Rank)(see Figure ). Baseline characteristics, procedural variables and discharge medications were analyzed in a Cox proportional hazards model (see Table ). DES use was an independent predictor of improved survival (Hazard Ratio for death 0.52, 95% CI .28–.95). Conclusions In an unselected, high risk population, long-term survival improved following the availability of drug eluting stents. After adjusting for potential confounding factors, DES use was an independent predictor of improved survival. Independent Predictors of Death in all 1,547 Patients

High-risk acute myelogenous leukemia: treatment today … and tomorrow

Hematology ◽  
2013 ◽  
Vol 2013 (1) ◽  
pp. 201-208 ◽  
Author(s):  
Gary J. Schiller
Keyword(s):  
High Risk ◽  
Acute Myelogenous Leukemia ◽  
Poor Response ◽  
Myelogenous Leukemia ◽  
Term Survival ◽  
Long Term Survival ◽  
Clinical Variables ◽  
Molecular Abnormalities ◽  
Acute Myelogenous

Abstract High-risk acute myelogenous leukemia (AML) constitutes a distinct subset of disease based on clinical and biological characteristics and comprises a significant percentage of all cases of adult AML. Biologic features such as distinct clonal cytogenetic and molecular abnormalities identify a subgroup of AML patients characterized by poor response to induction chemotherapy and poor long-term survival after treatment with consolidation chemotherapy. Clinical variables that predict for poor response include AML relapsed after less than 1 year of remission and AML characterized by resistance to conventional agents. We review here our understanding of the defining biologic subtypes of AML and discuss how adequate initial evaluation can be used to inform the choice of treatment. By defining high-risk biologic and clinical variables, a strong case can be made for treating patients with investigational agents, with treatment directed at distinct cytogenetic or molecular abnormalities. Allogeneic transplantation is the only form of therapy available outside of the setting of a clinical trial that may offer a chance for long-term survival for patients with high-risk AML.

High-Risk Neuroblastoma Treated With Tandem Autologous Peripheral-Blood Stem Cell–Supported Transplantation: Long-Term Survival Update

2006 ◽  
Vol 24 (18) ◽  
pp. 2891-2896 ◽  
Author(s):  
Rani E. George ◽  
Shuli Li ◽  
Cheryl Medeiros-Nancarrow ◽  
Donna Neuberg ◽  
Karen Marcus ◽  
...  
Keyword(s):  
Stem Cell ◽  
High Risk ◽  
Peripheral Blood ◽  
Peripheral Blood Stem Cell ◽  
Blood Stem Cell ◽  
Term Survival ◽  
Long Term Survival ◽  
Stem Cell Rescue ◽  
Cns Relapse

Purpose To provide an update on long-term survival of patients with high-risk neuroblastoma treated with tandem cycles of myeloablative therapy and peripheral-blood stem-cell rescue (PBSCR). Patients and Methods Ninety-seven patients with high-risk neuroblastoma were treated between 1994 and 2002. Patients underwent induction therapy with five cycles of standard agents, resection of the primary tumor and local radiation, and two consecutive courses of myeloablative therapy (including total-body irradiation) with PBSCR. Results Fifty-one patients have experienced relapse or died. Median follow-up time among the 46 patients who remain alive without progression is 5.6 years (range, 15.1 months to 9.9 years). Progression-free survival (PFS) rate at 5 years from diagnosis was 47% (95% CI, 36% to 56%), and PFS rate at 7 years was 45% (95% CI, 34% to 55%). Overall survival rate was 60% (95% CI, 48% to 69%) and 53% (95% CI, 40% to 64%) at 5 and 7 years, respectively. The 5- and 7- year PFS rates from time of first transplantation for 82 patients who completed both transplants were 54% (95% CI, 42% to 64%) and 52% (95% CI, 40% to 63%), respectively. Five patients died from treatment-related toxicity after tandem transplantation. Relapse occurred in 37 (42%) of 89 patients, mainly within 3 years of transplantation and primarily in diffuse osseous sites. No primary CNS relapse or secondary leukemia was seen. One patient developed synovial cell sarcoma 8 years after therapy. Conclusion High-dose therapy with tandem autologous stem-cell rescue is effective for treating high-risk neuroblastoma, with encouraging long-term survival. CNS relapse and secondary malignancies are rare after this therapy.

scholarly journals Long-Term Survival After Aortic Valve Replacement Among High-Risk Elderly Patients in the United States

Circulation ◽  
2012 ◽  
Vol 126 (13) ◽  
pp. 1621-1629 ◽  
Author(s):  
J. Matthew Brennan ◽  
Fred H. Edwards ◽  
Yue Zhao ◽  
Sean M. O'Brien ◽  
Pamela S. Douglas ◽  
...  
Keyword(s):  
United States ◽  
High Risk ◽  
Aortic Valve ◽  
Aortic Valve Replacement ◽  
Elderly Patients ◽  
Valve Replacement ◽  
The United States ◽  
Term Survival ◽  
Long Term Survival

LONG-TERM SURVIVAL AFTER RADICAL PROSTATECTOMY FOR PATIENTS WITH HIGH RISK PROSTATE CANCER IN THE PSA ERA

2008 ◽  
Vol 179 (4S) ◽  
pp. 552-553 ◽  
Author(s):  
Stephen A Boorjian ◽  
R Jeffrey Karnes ◽  
Laureano J Rangel ◽  
Eric J Bergstralh ◽  
Michael L Blute
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Radical Prostatectomy ◽  
Term Survival ◽  
Long Term Survival ◽  
High Risk Prostate Cancer ◽  
Risk Prostate Cancer
Sign in / Sign up

Export Citation Format

Share Document